MannKind Corp MNKD

US Biotechnology

$3.91 ▼ -4.87% ($-0.20)

📅 Earnings This Week

Open $4.09

Prev Close $4.11

Day Range $3.85 – $4.14

52W Range $2.23 – $6.51

Market Cap $1.25B

P/E (TTM) 213.00

Beta 1.12

EPS (TTM) $-0.08

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2004-07-28
Shares Out.	319,390,000
Website	mannkindcorp.com/ ↗
Phone	18009279800
Employees	592
Revenue	$90.2M
Gross Profit	$72.7M
Net Income	-$16.6M
Free Cash Flow	$13.2M
Total Assets	$744.4M
Total Liabilities	$803.6M
Equity	-$59.2M

About MannKind Corp

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

MannKind Corp is a publicly traded company under the ticker symbol MNKD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.